Table 5 Hypofractionated radiotherapy trials on primary and metastatic hepatic tumors
Author | Lesions (HCC/CCC/Metastatic tumor) | Treatment (prescription dose/fractionated frequency/isodose) | Median follow-up months (range) | Local control rate * | Survival rate | Median tumor volume cc (range) | Toxicity |
|---|---|---|---|---|---|---|---|
Takeda [9] 2008 | 16/0/0 | 35(20-50) gy/5-9/80% | 20.4 (8.1-33.1) | 100% at 1 year, 94% at 2 year | 100% at 2 year | 13.6 (3.4-72) | No SE |
TSE [11] 2008 | 31/10/0 | 36 (24-54) gy/6/NA | 17.6 (10.8-39.2) | 65% at 1 year (CR 5%, PR 44%, SD 42%) | 51% at 1 year (HCC 48% at 1 year) | 173 (9-1913) | No SE 5 patients (12%); grade 3 (liver) |
Present | 42/0/0 | 33 (30-39) gy/3/80% | 28.7 (8.4-49.1) | 72.0, 67.5% at 1 and 2, 3 and 4 year (CR 60%, PR 26%, SD 14%) | 92.9/77.3/58.6/58.6% at 1, 2, 3, 4 year | 15.4 (3.0-81.8) | 1 patient (2%); grade 4 (liver) |